Next earnings date: 11 Aug 2025
Regen BioPharma, Inc. – OTC:RGBPP
Regen BioPharma stock price today
Regen BioPharma stock price monthly change
Regen BioPharma stock price quarterly change
Regen BioPharma stock price yearly change
Regen BioPharma key metrics
Market Cap | 615.92K |
Enterprise value | 470.99K |
P/E | -0.41 |
EV/Sales | 1.99 |
EV/EBITDA | -0.10 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.15 |
Revenue | 236.56K |
EBITDA | -574.15K |
Income | -520.96K |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -1932.89% |
Oper. margin | -295.96% |
Gross margin | 37.27% |
EBIT margin | -295.96% |
EBITDA margin | -242.71% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRegen BioPharma stock price history
Regen BioPharma stock forecast
Regen BioPharma financial statements
| Mar 2023 | 59.06K | -19.02K | -32.22% |
|---|---|---|---|
| Jun 2023 | 59.06K | -99.21K | -167.98% |
| Sep 2023 | 59.36K | -280.24K | -472.06% |
| Mar 2024 | 59.06K | -122.47K | -207.35% |
| Mar 2023 | 406635 | 5.33M | 1312.33% |
|---|---|---|---|
| Jun 2023 | 285196 | 5.31M | 1863.34% |
| Sep 2023 | 353617 | 5.45M | 1543.37% |
| Mar 2024 | 140770 | 5.31M | 3776.87% |
| Mar 2023 | -53.04K | 0 | 100K |
|---|---|---|---|
| Jun 2023 | -87.00K | 0 | 0 |
| Sep 2023 | -23.40K | 0 | 143.75K |
| Mar 2024 | -209.32K | 0 | 162.93K |
Regen BioPharma alternative data
| Aug 2023 | 1 |
|---|---|
| Sep 2023 | 1 |
| Oct 2023 | 1 |
| Nov 2023 | 1 |
| Dec 2023 | 1 |
| Jan 2024 | 1 |
| Feb 2024 | 1 |
| Mar 2024 | 1 |
| Apr 2024 | 1 |
| May 2024 | 1 |
| Jun 2024 | 1 |
| Jul 2024 | 1 |
Regen BioPharma other data
-
What's the price of Regen BioPharma stock today?
One share of Regen BioPharma stock can currently be purchased for approximately $0.02.
-
When is Regen BioPharma's next earnings date?
Regen BioPharma, Inc. is estimated to report earnings on Monday, 11 Aug 2025.
-
Does Regen BioPharma pay dividends?
No, Regen BioPharma does not pay dividends.
-
How much money does Regen BioPharma make?
Regen BioPharma has a market capitalization of 615.92K.
-
What is Regen BioPharma's stock symbol?
Regen BioPharma, Inc. is traded on the OTC under the ticker symbol "RGBPP".
-
What is Regen BioPharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Regen BioPharma?
Shares of Regen BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Regen BioPharma have?
As Jul 2024, Regen BioPharma employs 1 workers.
-
When Regen BioPharma went public?
Regen BioPharma, Inc. is publicly traded company for more then 9 years since IPO on 20 Apr 2016.
-
What is Regen BioPharma's official website?
The official website for Regen BioPharma is regenbiopharmainc.com.
-
Where are Regen BioPharma's headquarters?
Regen BioPharma is headquartered at 4700 Spring Street, La Mesa, CA.
-
How can i contact Regen BioPharma?
Regen BioPharma's mailing address is 4700 Spring Street, La Mesa, CA and company can be reached via phone at +61 97225505.
Regen BioPharma company profile:
Regen BioPharma, Inc.
regenbiopharmainc.comOTC
1
Biotechnology
Healthcare
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is also involved in the development of its products, and therapies, including HemaXellarate, a cellular composition of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
La Mesa, CA 91942
CIK: 0001589150
:
:
